Evidence map›Paper›PMID 41417201›Full record

ArticleAnnals of nuclear medicine2026

Clinical value of clinicopathological, ultrasonographic features and fibroblast activation protein in evaluating the radioiodine treatment efficacy in papillary thyroid carcinoma.

Dongyue Chen, Li Zhu, Xue Li, Dan Wang, Yang Li, Xiankai Meng, Jian Tan, Danyang Sun, Zhaowei Meng

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dongyue ChenDepartment of Ultrasound, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Li ZhuDepartment of Ultrasound, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Xue LiDepartment of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Dan WangDepartment of Pathology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Yang LiDepartment of Pathology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Xiankai MengDepartment of Physics, Fudan University, Shanghai, 200438, China.
Jian TanDepartment of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Danyang SunDepartment of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Zhaowei MengDepartment of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, 300052, China. jamesmencius@163.com.ORCID http://orcid.org/0000-0001-6370-7394

Funding

Tianjin Key Medical Discipline (Specialty) Construction Project TJYXZDXK-001ATianjin Science and Technology Committee 21JCYBJC01820
6 · The paper itself

Abstract

purposeAlthough papillary thyroid carcinoma (PTC) is generally associated with a favorable prognosis, progression to radioactive iodine-refractory (RAIR) disease in metastatic cases leads to significantly poorer clinical outcomes. This study aimed to analyze the clinical value of clinicopathological, pre-operative ultrasonographic features, and fibroblast activation protein (FAP) immunoreactivity scores for the pretherapeutic prediction of the efficacy of radioiodine (RAI,

methodsA retrospective analysis was conducted on the medical records, clinicopathological data, and pre-operative ultrasonographic imaging of 167 PTC patients treated with

resultsBinary logistic regression analysis revealed that a maximum tumor diameter of ≥ 17.5 mm, microcalcifications, and a FAP immunoreactivity score of ≥ 3.44 were identified as independent risk factors for RAIR PTC. The combined model showed high sensitivity (75.9%), specificity (77.0%), and accuracy (AUC = 0.812) in the pretherapeutic prediction of

conclusionClinical significance was observed in the clinicopathological characteristics, ultrasonographic features of PTC and FAP immunoreactivity scores for evaluating

Indexed as

CarcinomaGelatinasesIodine RadioisotopesMembrane ProteinsSerine EndopeptidasesThyroid NeoplasmsAdultAgedCarcinoma, PapillaryEndopeptidasesFemaleHumansMaleMiddle AgedRetrospective StudiesThyroid Cancer, PapillaryEndopeptidasesGelatinasesIodine RadioisotopesMembrane ProteinsSerine Endopeptidases131I therapeutic efficacyClinicopathological and ultrasonographic featureFibroblast activation proteinNomogramRadioactive iodine-refractory papillary thyroid carcinoma

Identifiers

PMID41417201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.